|By JCN Newswire||
|May 29, 2014 06:26 AM EDT||
Tokyo, May 29, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that the antiemetic agent ALOXI (generic name: palonosetron HCI) has been approved in the U.S. for an additional indication regarding the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy, in children aged 1 month to up to 17 years by the U.S. Food and Drug Administration (FDA). Despite peak cancer incidence among children occurring within the first year of life, this is the first product for chemotherapy-induced nausea and vomiting (CINV) prevention approved in patients aged between 1 and 6 months after birth. Eisai's U.S subsidiary Eisai Inc. markets this product based on having received exclusive marketing rights from Helsinn Healthcare S.A. (Headquarters: Lugano, Switzerland) for the U.S.
This approval was based on a randomized, double-blind, non-inferiority pivotal trial comparing ALOXI with ondansetron in pediatric patients, which was conducted in response to a Written Request by the FDA. The primary endpoint of Complete Response, defined as no vomiting, no retching and no antiemesis rescue medication required within the first 24 hours after chemotherapy, was achieved in 59.4% of patients who received ALOXI (20 mcg/kg, single-dose IV) versus 58.6% of patients who received the ondansetron regimen. Treatment-emergent adverse events (TEAEs) were comparable across both arms, with the most frequently reported TEAE in the ALOXI group being headaches. While this study demonstrated that pediatric patients require a higher palonosetron dose based on weight than adults to prevent CINV, the safety profile for ALOXI was confirmed as being consistent with the established profile in adults.
Furthermore, the clinical trial data has met the FDA's Written Request requirements for pediatric exclusivity, resulting in an additional six months of U.S. market exclusivity for the drug, which will now expire on October 13, 2015.
As there has been a significant unmet need for preventive treatment of nausea and vomiting induced by chemotherapy for children, through the approval of this product, Eisai continues to make further contributions to address the needs of, and increase the benefits provided to, pediatric patients undergoing chemotherapy and their families.
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department, Eisai Co., Ltd. +81-3-3817-5120
Copyright 2014 JCN Newswire. All rights reserved. www.japancorp.net
As ridesharing competitors and enhanced services increase, notable changes are occurring in the transportation model. Despite the cost-effective means and flexibility of ridesharing, both drivers and users will need to be aware of the connected environment and how it will impact the ridesharing experience. In his session at @ThingsExpo, Timothy Evavold, Executive Director Automotive at Covisint, will discuss key challenges and solutions to powering a ride sharing and/or multimodal model in the a...
Oct. 1, 2016 01:15 AM EDT Reads: 717
In his general session at 18th Cloud Expo, Lee Atchison, Principal Cloud Architect and Advocate at New Relic, discussed cloud as a ‘better data center’ and how it adds new capacity (faster) and improves application availability (redundancy). The cloud is a ‘Dynamic Tool for Dynamic Apps’ and resource allocation is an integral part of your application architecture, so use only the resources you need and allocate /de-allocate resources on the fly.
Oct. 1, 2016 01:15 AM EDT Reads: 3,041
Oct. 1, 2016 12:15 AM EDT Reads: 1,423
Sep. 30, 2016 11:45 PM EDT Reads: 5,439
Sep. 30, 2016 11:30 PM EDT Reads: 489
Sep. 30, 2016 11:30 PM EDT Reads: 759
Sep. 30, 2016 10:45 PM EDT Reads: 507
Sep. 30, 2016 10:45 PM EDT Reads: 1,538
Sep. 30, 2016 10:00 PM EDT Reads: 1,262
Sep. 30, 2016 09:45 PM EDT Reads: 2,848
Sep. 30, 2016 09:30 PM EDT Reads: 4,121
Sep. 30, 2016 09:00 PM EDT Reads: 4,062
Sep. 30, 2016 09:00 PM EDT Reads: 2,834
Sep. 30, 2016 08:45 PM EDT Reads: 497
Sep. 30, 2016 08:30 PM EDT Reads: 3,200